Stammdaten
Acumen Pharmaceuticals, Inc., ein klinisches Biopharmaka-Unternehmen, entdeckt und entwickelt Therapien zur Behandlung der Alzheimer-Krankheit. Das Unternehmen konzentriert sich auf die Weiterentwicklung eines gezielten Immuntherapie-Wirkstoffkandidaten ACU193, einem humanisierten monoklonalen Antikörper, der sich in der Phase-I-klinischen Phase befindet, um lösliche Amyloid-Beta-Oligomere anzusprechen. Acumen Pharmaceuticals, Inc. wurde 1996 gegründet und hat seinen Sitz in Charlottesville, Virginia. KI
Unternehmen & Branche
| Name | Acumen Pharmaceuticals, Inc. |
|---|---|
| Ticker | ABOS |
| CIK | 0001576885 |
| Börse | Nasdaq |
| Sektor | Gesundheit |
| Industrie | Biotechnologie (Forschung) |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | 00509G209 |
|---|---|
| ISIN | US00509G2093 |
| Typ | Common Stock |
| Marktkapitalisierung | 138,1 Mio. USD |
| Beta | 0,36 |
Sitz & Kontakt
| Sitz (Inkorporation) | DE |
|---|---|
| Geschäftsadresse | 1210-1220 WASHINGTON STREET SUITE 210, 02465 NEWTON, MA |
| Telefon | 617-344-4190 |
| EIN (IRS) | 36-4108129 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Emerging growth company |
Bewertung
| KBV (P/B) | 1,96 vs. 1,22 (2021) ▲ |
|---|---|
| FCF-Rendite | -83,7 % vs. -6,6 % (2021) ▼ |
Qualität & Bilanz
| ROIC | -172,3 % vs. -44,7 % (2021) ▼ |
|---|---|
| Zinsdeckungsgrad | -29,3 |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KBV (P/B) | 1,22 | 1,17 | 0,83 | 0,57 | 1,81 | 1,58 | |
| FCF-Rendite | -6,6 % | -15,9 % | -19,4 % | -83,4 % | -90,4 % | -76,4 % | |
| Qualität & Bilanz | |||||||
| ROIC | -44,7 % | -22,7 % | -17,6 % | -48,4 % | -172,3 % | -129,5 % | |
| Zinsdeckungsgrad | – | – | -105,2 | -28,0 | -29,3 | -26,8 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
ABOS
Acumen Pharmaceuticals, Inc.
ⓘ
Eingeschränkte Aussagekraft — erst 62 % der Signal-Gewichte sind mit Daten unterlegt.
Effektiv
Neutral
Handelsvolumen
Sehr niedrig
Insider
0,0
Keine Insider-Käufe
Institutionell
94,0
20 neu, 32 erhöht, 32,3M $ netto
Aktivist
13,6
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bärisch | 10 % | 2.38 | -11.3 % vs SMA50 | |
| Kurs vs SMA200 | Bärisch | 15 % | 2.35 | -10.3 % vs SMA200 | |
| EMA20 vs EMA50 | Bärisch | 5 % | 2.31 | EMA50: 2.39 | |
| MACD-Histogramm | Bärisch | 10 % | -0.028 | Bearisch | |
| RSI(14) | Neutral | 10 % | 39.7 | Neutral (30–70) | |
| Stoch %K(14) | Bullisch | 5 % | 3.0 | Überverkauft | |
| ADX(14)+DI | Neutral | 10 % | 19.3 | +DI: 19.1 / −DI: 25.1 | |
| Z-Score(60) | Bullisch | 5 % | -1.60 | Extrem überverkauft | |
| 52W-Position | Neutral | 5 % | 41.1 % | Hoch 3.37 / Tief 1.23 | |
| Bollinger(20,2σ) | Bullisch | 5 % | 18.5 % | Upper 2.86 / Mid 2.40 / Lower 1.94 | |
| LinReg-Slope(60) | Neutral | 10 % | -0.0020 | R²=0.04 / annualisiert -21.5 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-06-17 | Porter Derrell | Director | Open Market Sale | -13.040 | 2,33 | -30.318,00 | -232,7% | |
| 2026-06-16 | Porter Derrell | Director | Open Market Sale | -12.800 | 2,33 | -29.772,80 | -228,5% | |
| 2026-06-15 | Porter Derrell | Director | Open Market Sale | -6.460 | 2,35 | -15.148,70 | -116,3% | |
| 2026-06-09 | Fountain Nathan B | Director | Open Market Sale | -6.400 | 2,23 | -14.272,64 | -109,5% | |
| 2026-03-06 | Meisner Derek M | Officer, Chief Legal Officer & Corp Sec | Open Market Sale | -2.090 | 3,26 | -6.813,40 | -52,3% | |
| 2026-02-27 | Meisner Derek M | Officer, Chief Legal Officer & Corp Sec | Open Market Sale | -9.406 | 3,01 | -28.311,12 | -217,3% | |
| 2026-01-28 | Meisner Derek M | Officer, Chief Legal Officer & Corp Sec | Open Market Sale | -2.671 | 3,00 | -8.017,27 | -61,5% | |
| 2026-01-26 | Meisner Derek M | Officer, Chief Legal Officer & Corp Sec | Open Market Sale | -15.085 | 3,00 | -45.262,54 | -347,4% | |
| 2026-01-23 | Meisner Derek M | Officer, Chief Legal Officer & Corp Sec | Open Market Sale | -5.633 | 1,90 | -10.717,91 | -82,3% | |
| 2026-01-22 | Meisner Derek M | Officer, Chief Legal Officer & Corp Sec | Open Market Sale | -1.054 | 1,84 | -1.939,36 | -14,9% | |
| 2026-01-22 | Barton Russell | Officer, Chief Operating Officer | Open Market Sale | -462 | 1,84 | -850,08 | -6,5% | |
| 2026-01-22 | OConnell Daniel Joseph | Director, Officer, Chief Executive Officer | Open Market Sale | -2.689 | 1,88 | -5.065,54 | -38,9% | |
| 2026-01-22 | Zuga Matt | Officer, CFO & Chief Business Officer | Open Market Sale | -1.687 | 1,86 | -3.137,82 | -24,1% | |
| 2026-01-22 | Siemers Eric | Officer, Chief Medical Officer | Open Market Sale | -895 | 1,82 | -1.628,90 | -12,5% | |
| 2026-01-21 | Zuga Matt | Officer, CFO & Chief Business Officer | Open Market Sale | -2.473 | 1,81 | -4.469,21 | -34,3% | |
| 2026-01-21 | Meisner Derek M | Officer, Chief Legal Officer & Corp Sec | Open Market Sale | -2.247 | 1,81 | -4.063,25 | -31,2% | |
| 2026-01-21 | Siemers Eric | Officer, Chief Medical Officer | Open Market Sale | -2.331 | 1,80 | -4.203,96 | -32,3% | |
| 2026-01-21 | OConnell Daniel Joseph | Director, Officer, Chief Executive Officer | Open Market Sale | -9.346 | 1,81 | -16.927,48 | -129,9% | |
| 2026-01-21 | Barton Russell | Officer, Chief Operating Officer | Open Market Sale | -2.315 | 1,81 | -4.180,89 | -32,1% | |
| 2026-01-12 | OConnell Daniel Joseph | Director, Officer, Chief Executive Officer | Open Market Sale | -5.388 | 1,73 | -9.306,69 | -71,4% | |
| 2026-01-12 | Meisner Derek M | Officer, Chief Legal Officer & Corp Sec | Open Market Sale | -8.548 | 1,71 | -14.658,11 | -112,5% | |
| 2026-01-09 | Meisner Derek M | Officer, Chief Legal Officer & Corp Sec | Open Market Sale | -5.200 | 1,76 | -9.169,16 | -70,4% | |
| 2026-01-09 | OConnell Daniel Joseph | Director, Officer, Chief Executive Officer | Open Market Sale | -12.941 | 1,76 | -22.831,81 | -175,2% | |
| 2026-01-08 | Meisner Derek M | Officer, Chief Legal Officer & Corp Sec | Open Market Sale | -30.092 | 1,82 | -54.866,74 | -421,1% | |
| 2026-01-08 | Barton Russell | Officer, Chief Operating Officer | Open Market Sale | -3.530 | 1,86 | -6.561,56 | -50,4% | |
| 2026-01-08 | OConnell Daniel Joseph | Director, Officer, Chief Executive Officer | Open Market Sale | -8.143 | 1,82 | -14.815,37 | -113,7% | |
| 2026-01-08 | Zuga Matt | Officer, CFO & Chief Business Officer | Open Market Sale | -6.888 | 1,82 | -12.512,74 | -96,0% | |
| 2026-01-08 | Doherty James J. | Officer, President and CDO | Open Market Sale | -6.467 | 1,82 | -11.768,65 | -90,3% | |
| 2026-01-08 | Meisner Derek M | Officer, Chief Legal Officer & Corp Sec | Open Market Sale | -6.819 | 1,82 | -12.379,21 | -95,0% | |
| 2026-01-07 | Schacterle Amy | Officer, Chief Regulatory Officer | Open Market Sale | -1.097 | 1,98 | -2.176,23 | -16,7% | |
| 2026-01-07 | Zuga Matt | Officer, CFO & Chief Business Officer | Open Market Sale | -1.700 | 1,99 | -3.376,54 | -25,9% | |
| 2026-01-07 | Doherty James J. | Officer, President and CDO | Open Market Sale | -1.700 | 1,99 | -3.379,43 | -25,9% | |
| 2026-01-07 | Barton Russell | Officer, Chief Operating Officer | Open Market Sale | -1.700 | 1,99 | -3.378,07 | -25,9% | |
| 2026-01-07 | Meisner Derek M | Officer, Chief Legal Officer & Corp Sec | Open Market Sale | -10.070 | 1,99 | -20.035,27 | -153,8% | |
| 2026-01-07 | Meisner Derek M | Officer, Chief Legal Officer & Corp Sec | Open Market Sale | -1.700 | 1,99 | -3.378,92 | -25,9% | |
| 2026-01-07 | OConnell Daniel Joseph | Director, Officer, Chief Executive Officer | Open Market Sale | -37.755 | 1,99 | -74.981,43 | -575,5% | |
| 2026-01-07 | Zuga Matt | Officer, CFO & Chief Business Officer | Open Market Sale | -4.105 | 2,00 | -8.189,48 | -62,9% | |
| 2026-01-06 | Zuga Matt | Officer, CFO & Chief Business Officer | Open Market Sale | -5.100 | 1,97 | -10.027,62 | -77,0% | |
| 2026-01-06 | Barton Russell | Officer, Chief Operating Officer | Open Market Sale | -3.618 | 1,97 | -7.114,44 | -54,6% | |
| 2026-01-06 | OConnell Daniel Joseph | Director, Officer, Chief Executive Officer | Open Market Sale | -5.102 | 1,97 | -10.031,55 | -77,0% | |
| 2026-01-06 | Siemers Eric | Officer, Chief Medical Officer | Open Market Sale | -6.834 | 1,97 | -13.442,48 | -103,2% | |
| 2026-01-06 | Meisner Derek M | Officer, Chief Legal Officer & Corp Sec | Open Market Sale | -7.097 | 1,97 | -13.961,22 | -107,1% | |
| 2026-01-06 | Meisner Derek M | Officer, Chief Legal Officer & Corp Sec | Open Market Sale | -3.801 | 1,97 | -7.476,57 | -57,4% | |
| 2026-01-05 | Siemers Eric | Officer, Chief Medical Officer | Open Market Sale | -4.000 | 1,96 | -7.834,80 | -60,1% | |
| 2026-01-05 | Meisner Derek M | Officer, Chief Legal Officer & Corp Sec | Open Market Sale | -4.000 | 1,96 | -7.838,00 | -60,2% | |
| 2026-01-05 | OConnell Daniel Joseph | Director, Officer, Chief Executive Officer | Open Market Sale | -4.649 | 1,97 | -9.163,18 | -70,3% | |
| 2026-01-05 | Zuga Matt | Officer, CFO & Chief Business Officer | Open Market Sale | -4.000 | 1,96 | -7.842,40 | -60,2% | |
| 2026-01-05 | Barton Russell | Officer, Chief Operating Officer | Open Market Sale | -4.000 | 1,96 | -7.832,40 | -60,1% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 3394 von typischerweise 8409 Fonds (40 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 20.992.669 | 0 | 20.992.669 | 49.542.699 | Neu | +100,0% | |
| Sands Capital Alternatives, LLC | 3.720.105 | 0 | 3.720.105 | 8.779.448 | Neu | +100,0% | |
| Alyeska Investment Group, L.P. | 2.454.754 | 0 | 2.454.754 | 5.776.765 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 2.305.096 | 0 | 2.305.096 | 5.440.027 | Neu | +100,0% | |
| ADAR1 Capital Management, LLC | 2.156.334 | 0 | 2.156.334 | 5.088.948 | Neu | +100,0% | |
| Knollwood Investment Advisory, LLC | 1.628.510 | 0 | 1.628.510 | 3.843.284 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.506.277 | 0 | 1.506.277 | 3.554.814 | Neu | +100,0% | |
| FMR LLC | 1.157.346 | 0 | 1.157.346 | 2.731.337 | Neu | +100,0% | |
| Ikarian Capital, LLC | 1.053.797 | 0 | 1.053.797 | 2.486.960 | Neu | +100,0% | |
| Hudson Bay Capital Management LP | 968.940 | 0 | 968.940 | 2.286.698 | Neu | +100,0% | |
| Pathstone Holdings, LLC | 859.110 | 0 | 859.110 | 2.027.500 | Neu | +100,0% | |
| SG Americas Securities, LLC | 719.257 | 0 | 719.257 | 1.697.000 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 713.376 | 0 | 713.376 | 1.683.567 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 659.675 | 0 | 659.675 | 1.556.833 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 530.812 | 0 | 530.812 | 1.252.716 | Neu | +100,0% | |
| Laurion Capital Management LP | 525.444 | 0 | 525.444 | 1.240.048 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 473.946 | 0 | 473.946 | 1.118.513 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 416.238 | 0 | 416.238 | 982.755 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 320.216 | 0 | 320.216 | 755.710 | Neu | +100,0% | |
| BOOTHBAY FUND MANAGEMENT, LLC | 273.012 | 0 | 273.012 | 644.308 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 206.683 | 0 | 206.683 | 487.772 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 192.889 | 0 | 192.889 | 455.218 | Neu | +100,0% | |
| ACADIAN ASSET MANAGEMENT LLC | 185.850 | 0 | 185.850 | 435.000 | Neu | +100,0% | |
| BlackRock, Inc. | 178.326 | 0 | 178.326 | 420.849 | Neu | +100,0% | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 176.171 | 0 | 176.171 | 415.764 | Neu | +100,0% | |
| STATE STREET CORP | 151.728 | 0 | 151.728 | 358.078 | Neu | +100,0% | |
| MORGAN STANLEY | 144.584 | 0 | 144.584 | 341.219 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 132.261 | 0 | 132.261 | 312.135 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 120.388 | 0 | 120.388 | 284.116 | Neu | +100,0% | |
| DIMENSIONAL FUND ADVISORS LP | 119.756 | 0 | 119.756 | 281.763 | Neu | +100,0% | |
| PFG Investments, LLC | 94.250 | 80.850 | 13.400 | 251.648 | Aufgestockt | +16,6% | |
| CATALYST FINANCIAL PARTNERS LLC | 89.699 | 89.699 | 0 | 239.496 | Unverändert | 0,0% | |
| SIMPLEX TRADING, LLC | 100.414 | 0 | 100.414 | 236.977 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 75.212 | 0 | 75.212 | 177.500 | Neu | +100,0% | |
| Point72 Asset Management, L.P. | 67.375 | 0 | 67.375 | 159.005 | Neu | +100,0% | |
| Prospera Financial Services Inc | 50.000 | 50.000 | 0 | 133.500 | Unverändert | 0,0% | |
| Catalyst Funds Management Pty Ltd | 45.600 | 0 | 45.600 | 107.616 | Neu | +100,0% | |
| NEW YORK STATE COMMON RETIREMENT FUND | 36.200 | 0 | 36.200 | 96.654 | Neu | +100,0% | |
| Verdad Advisers, LP | 37.278 | 0 | 37.278 | 87.976 | Neu | +100,0% | |
| UBS Group AG | 37.146 | 0 | 37.146 | 87.665 | Neu | +100,0% | |
| Rangeley Capital, LLC | 35.000 | 0 | 35.000 | 82.600 | Neu | +100,0% | |
| Y-Intercept (Hong Kong) Ltd | 29.540 | 0 | 29.540 | 78.872 | Neu | +100,0% | |
| BARCLAYS PLC | 30.679 | 0 | 30.679 | 72.402 | Neu | +100,0% | |
| Intrepid Financial Planning Group LLC | 30.150 | 0 | 30.150 | 71.154 | Neu | +100,0% | |
| OMERS ADMINISTRATION Corp | 28.600 | 0 | 28.600 | 67.496 | Neu | +100,0% | |
| AXQ CAPITAL, LP | 28.487 | 0 | 28.487 | 67.229 | Neu | +100,0% | |
| Police & Firemen's Retirement System of New Jersey | 19.393 | 0 | 19.393 | 51.779 | Neu | +100,0% | |
| Independent Advisor Alliance | 19.000 | 0 | 19.000 | 44.840 | Neu | +100,0% | |
| Factor Wealth Management LTD | 16.500 | 16.500 | 0 | 44.055 | Unverändert | 0,0% | |
| PINNACLE ASSOCIATES LTD | 18.020 | 0 | 18.020 | 42.527 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 3394 von typischerweise 8409 Fonds (40 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| PFG Investments, LLC | 94.250 | 80.850 | +16,6% | 251.648 | 26,83 | 0 % | 4 Q |
| CATALYST FINANCIAL PARTNERS LLC | 89.699 | 89.699 | 0,0% | 239.496 | 25,54 | 0 % | 13 Q |
| Prospera Financial Services Inc | 50.000 | 50.000 | 0,0% | 133.500 | 14,24 | 0 % | 3 Q |
| NEW YORK STATE COMMON RETIREMENT FUND | 36.200 | 0 | +100,0% | 96.654 | 10,31 | 100 % | 6 Q |
| Y-Intercept (Hong Kong) Ltd | 29.540 | 0 | +100,0% | 78.872 | 8,41 | 100 % | 4 Q |
| Police & Firemen's Retirement System of New Jersey | 19.393 | 0 | +100,0% | 51.779 | 5,52 | 100 % | 1 Q |
| Factor Wealth Management LTD | 16.500 | 16.500 | 0,0% | 44.055 | 4,70 | 0 % | 7 Q |
| Mesirow Financial Investment Management, Inc. | 11.305 | 11.305 | 0,0% | 30.184 | 3,22 | 100 % | 2 Q |
| TFC Financial Management, Inc. | 2.500 | 2.500 | 0,0% | 6.675 | 0,71 | 0 % | 4 Q |
| Sterling Capital Management LLC | 952 | 0 | +100,0% | 2.542 | 0,27 | 0 % | 4 Q |
| EverSource Wealth Advisors, LLC | 407 | 407 | 0,0% | 1.087 | 0,12 | 100 % | 6 Q |
| SBI Securities Co., Ltd. | 291 | 303 | -4,0% | 777 | 0,08 | 100 % | 7 Q |
| Farther Finance Advisors, LLC | 200 | 200 | 0,0% | 534 | 0,06 | 0 % | 5 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 13 | 0,4 | 1 |
| 31.03.2026 | ✓ | 84 | 47,5 | 112 |
| 31.12.2025 | ✓ | 71 | 37,7 | 80 |
| 30.09.2025 | ✓ | 69 | 36,9 | 63 |
| 30.06.2025 | ✓ | 71 | 38,5 | 45 |
| 31.03.2025 | ✓ | 80 | 40,9 | 46 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| Verdad Advisers, LP | 37.278 | 87.976 |
| Rangeley Capital, LLC | 35.000 | 82.600 |
| AXQ CAPITAL, LP | 28.487 | 67.229 |
| AMERICAN CENTURY COMPANIES INC | 17.929 | 42.312 |
| SIMPLEX TRADING, LLC | 17.414 | 41.097 |
| CAPTRUST FINANCIAL ADVISORS | 15.757 | 37.187 |
| Brevan Howard Capital Management LP | 15.385 | 36.309 |
| Squarepoint Ops LLC | 15.015 | 35.435 |
| HRT FINANCIAL LP | 13.162 | 31.000 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 13.011 | 30.706 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 20.992.669 | 6.060.606 | +40.6 % | 49.542.699 |
| Alyeska Investment Group, L.P. | 2.454.754 | 1.515.151 | +161.3 % | 5.776.765 |
| ADAR1 Capital Management, LLC | 2.156.334 | 1.265.151 | +142.0 % | 5.088.948 |
| Ikarian Capital, LLC | 1.053.797 | 799.485 | +314.4 % | 2.486.960 |
| TWO SIGMA INVESTMENTS, LP | 530.812 | 387.591 | +270.6 % | 1.252.716 |
| SG Americas Securities, LLC | 719.257 | 318.210 | +79.3 % | 1.697.000 |
| Sands Capital Alternatives, LLC | 3.720.105 | 303.030 | +8.9 % | 8.779.448 |
| Hudson Bay Capital Management LP | 968.940 | 243.940 | +33.6 % | 2.286.698 |
| BOOTHBAY FUND MANAGEMENT, LLC | 273.012 | 233.427 | +589.7 % | 644.308 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 601.476 | 228.278 | +61.2 % | 1.419.483 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| FMR LLC | 1.157.346 | -870.151 | -42.9 % | 2.731.337 |
| Laurion Capital Management LP | 525.444 | -341.602 | -39.4 % | 1.240.048 |
| JANE STREET GROUP, LLC | 89.661 | -52.462 | -36.9 % | 211.599 |
| MORGAN STANLEY | 144.584 | -22.321 | -13.4 % | 341.219 |
| Tower Research Capital LLC (TRC) | 118 | -4.339 | -97.4 % | 278 |
| Larson Financial Group LLC | 20 | -4.328 | -99.5 % | 47 |
| GROUP ONE TRADING LLC | 1.475 | -3.277 | -69.0 % | 3.481 |
| OSAIC HOLDINGS, INC. | 5.351 | -1.500 | -21.9 % | 12.628 |
| CWM, LLC | 87 | -60 | -40.8 % | 205 |
| SBI Securities Co., Ltd. | 303 | -20 | -6.2 % | 715 |
Zusätzlich aktuell von 20 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 07.04.2026 | James B. Murray Jr. | Passiv (13G) | 5,00 % | 3.611.360 | Neu | |
| 17.03.2026 | RA Capital Management, L.P. (+2) | Aktivist (13D/A) | 29,50 % | 21.101.669 | +4,70 pp | |
| 17.03.2026 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 26,80 % | 19.103.785 | +5,30 pp | |
| 04.11.2025 | Rupert H. Johnson, Jr. (+1) | Passiv (13G/A) | Ausstieg | 0 | Neu | |
| 04.11.2025 | Franklin Resources, Inc. | Passiv (13G/A) | 3,80 % | 2.305.096 | -2,00 pp | |
| 13.08.2025 | Sands Capital Life Sciences Pulse Fund, LLC (+1) | Passiv (13G/A) | 1,90 % | 1.146.173 | -0,90 pp | |
| 13.08.2025 | Sands Capital Alternatives, LLC (+1) | Passiv (13G/A) | 5,60 % | 3.417.075 | Neu | |
| 13.08.2025 | Sands Capital Ventures Discovery Fund III, L.P. | Passiv (13G/A) | 1,90 % | 1.124.729 | -0,80 pp | |
| 31.03.2025 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 21,50 % | 13.043.179 | -1,10 pp | |
| 31.03.2025 | RA Capital Management, L.P. (+2) | Aktivist (13D/A) | 24,80 % | 15.016.063 | -1,10 pp | |
| 14.02.2024 | Deep Track Biotechnology Master Fund, Ltd. (+2) | Passiv (13G/A) | Ausstieg | 0 | -9,66 pp | |
| 06.02.2024 | Franklin Resources, Inc. | Passiv (13G) | 5,80 % | 3.358.809 | Neu | |
| 06.02.2024 | Rupert H. Johnson, Jr.2 (+1) | Passiv (13G) | 0,00 % | 4 | Neu | |
| 06.02.2024 | Franklin Advisers, Inc. | Passiv (13G) | 5,70 % | 3.327.809 | Neu | |
| 24.01.2024 | James B. Murray, Jr. | Passiv (13G/A) | 4,60 % | 2.681.057 | Neu | |
| 25.07.2023 | RA Capital Management, L.P. (+2) | Aktivist (13D/A) | 25,90 % | 14.981.618 | +1,70 pp | |
| 25.07.2023 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 22,60 % | 13.043.179 | +3,10 pp | |
| 14.02.2023 | The Paul B. Manning Revocable Trust dated May 10, 2000 | Passiv (13G/A) | 6,20 % | 2.547.143 | -1,30 pp | |
| 14.02.2023 | BKB Growth Investments, LLC | Passiv (13G/A) | 1,60 % | 657.985 | 0,00 pp | |
| 14.02.2023 | Paul B. Manning | Passiv (13G/A) | 7,80 % | 32.051.283 | -2,10 pp | |
| 14.02.2023 | Sands Capital Life Sciences Pulse Fund, LLC (+1) | Passiv (13G/A) | 2,80 % | 1.146.173 | Neu | |
| 14.02.2023 | Sands Capital Ventures, LLC (+1) | Passiv (13G/A) | 8,30 % | 34.170.751 | Neu | |
| 14.02.2023 | Sands Capital Ventures Discovery Fund III, L.P. | Passiv (13G/A) | 2,70 % | 1.124.729 | Neu | |
| 14.02.2023 | Deep Track Biotechnology Master Fund, Ltd. (+2) | Passiv (13G/A) | 9,66 % | 3.952.000 | +3,69 pp | |
| 07.10.2022 | . BlackRock, Inc. | Passiv (13G/A) | 2,80 % | 1.115.027 | -4,90 pp | |
| 16.02.2022 | : Robert D. Hardie (+1) | Passiv (13G) | 8,50 % | 3.451.152 | Neu | |
| 15.02.2022 | BKB Growth Investments, LLC | Passiv (13G) | 1,60 % | 657.985 | Neu | |
| 15.02.2022 | Paul B. Manning | Passiv (13G) | 9,90 % | 40.106.783 | Neu | |
| 15.02.2022 | The Paul B. Manning Revocable Trust dated May 10, 2000 | Passiv (13G) | 7,50 % | 3.040.193 | Neu | |
| 14.02.2022 | James B. Murray, Jr. | Passiv (13G) | 6,40 % | 2.581.057 | Neu | |
| 04.02.2022 | . BlackRock, Inc. | Passiv (13G) | 7,70 % | 3.109.670 | Neu | |
| 27.01.2022 | Deep Track Biotechnology Master Fund, Ltd. (+2) | Passiv (13G) | 5,97 % | 2.414.917 | Neu | |
| 13.09.2021 | RA Capital Healthcare Fund, L.P. | Aktivist (13D/A) | 19,50 % | 7.881.889 | -0,90 pp | |
| 13.09.2021 | RA Capital Management, L.P. (+2) | Aktivist (13D/A) | 24,20 % | 9.774.551 | -1,10 pp |
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | – | -20.737.000 $ | -0,33 $ | 133.629.000 $ | 87.476.000 $ |
| 2025-12-31 | 10-K | – | -121.335.000 $ | -2,00 $ | 122.833.000 $ | 70.430.000 $ |
| 2025-09-30 | 10-Q | – | -26.451.000 $ | -0,44 $ | 142.221.000 $ | 93.173.000 $ |
| 2025-06-30 | 10-Q | – | -40.950.000 $ | -0,68 $ | 171.897.000 $ | 117.077.000 $ |
| 2025-03-31 | 10-Q | – | -28.796.000 $ | -0,48 $ | 204.478.000 $ | 155.521.000 $ |
| 2024-12-31 | 10-K | – | -102.329.000 $ | -1,71 $ | 238.992.000 $ | 181.816.000 $ |
| 2024-09-30 | 10-Q | – | -29.765.000 $ | -0,50 $ | 266.975.000 $ | 217.202.000 $ |
| 2024-06-30 | 10-Q | – | -20.537.000 $ | -0,34 $ | 288.913.000 $ | 243.947.000 $ |
| 2024-03-31 | 10-Q | – | -14.873.000 $ | -0,25 $ | 300.967.000 $ | 262.034.000 $ |
| 2023-12-31 | 10-K | – | -52.371.000 $ | -1,08 $ | 310.125.000 $ | 266.973.000 $ |
| 2023-09-30 | 10-Q | – | -12.957.000 $ | -0,24 $ | 286.371.000 $ | 280.273.000 $ |
| 2023-06-30 | 10-Q | – | -11.610.000 $ | -0,28 $ | 177.405.000 $ | 168.874.000 $ |
| 2023-03-31 | 10-Q | – | -11.307.000 $ | -0,28 $ | 187.864.000 $ | 179.085.000 $ |
| 2022-12-31 | 10-K | – | -42.856.000 $ | -1,06 $ | 196.587.000 $ | 188.775.000 $ |
| 2022-09-30 | 10-Q | – | -10.710.000 $ | -0,26 $ | 203.264.000 $ | 196.651.000 $ |
| 2022-06-30 | 10-Q | – | -10.151.000 $ | -0,25 $ | 211.678.000 $ | 206.519.000 $ |
| 2022-03-31 | 10-Q | – | -9.129.000 $ | -0,23 $ | 220.087.000 $ | 216.089.000 $ |
| 2021-12-31 | 10-K | – | -100.606.000 $ | -5,02 $ | 230.330.000 $ | 225.183.000 $ |
| 2021-09-30 | 10-Q | – | -3.902.000 $ | -0,10 $ | 234.849.000 $ | 233.360.000 $ |
| 2021-06-30 | 10-Q | – | -61.358.000 $ | -141,93 $ | 72.943.000 $ | -106.079.000 $ |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 12.05.2026 | – | -0,33 |
| Q3 2025 | 30.09.2025 | 12.11.2025 | – | -0,44 |
| Q2 2025 | 30.06.2025 | 12.08.2025 | – | -0,68 |
| Q1 2025 | 31.03.2025 | 13.05.2025 | – | -0,48 |
| Q3 2024 | 30.09.2024 | 12.11.2024 | – | -0,50 |
| Q2 2024 | 30.06.2024 | 13.08.2024 | – | -0,34 |
| Q1 2024 | 31.03.2024 | 14.05.2024 | – | -0,25 |
| Q3 2023 | 30.09.2023 | 13.11.2023 | – | -0,24 |
| Q2 2023 | 30.06.2023 | 08.08.2023 | – | -0,28 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 12.05.2026 | 10-Q | 31.03.2026 | 42 Tage | SEC » |
| 26.03.2026 | 10-K | 31.12.2025 | 85 Tage | SEC » |
| 12.11.2025 | 10-Q | 30.09.2025 | 43 Tage | SEC » |
| 12.08.2025 | 10-Q | 30.06.2025 | 43 Tage | SEC » |
| 13.05.2025 | 10-Q | 31.03.2025 | 43 Tage | SEC » |
| 27.03.2025 | 10-K | 31.12.2024 | 86 Tage | SEC » |
| 12.11.2024 | 10-Q | 30.09.2024 | 43 Tage | SEC » |
| 13.08.2024 | 10-Q | 30.06.2024 | 44 Tage | SEC » |
| 14.05.2024 | 10-Q | 31.03.2024 | 44 Tage | SEC » |
| 26.03.2024 | 10-K | 31.12.2023 | 86 Tage | SEC » |
| 13.11.2023 | 10-Q | 30.09.2023 | 44 Tage | SEC » |
| 08.08.2023 | 10-Q | 30.06.2023 | 39 Tage | SEC » |
| 09.05.2023 | 10-Q | 31.03.2023 | 39 Tage | SEC » |
| 27.03.2023 | 10-K | 31.12.2022 | 86 Tage | SEC » |
| 14.11.2022 | 10-Q | 30.09.2022 | 45 Tage | SEC » |
| 15.08.2022 | 10-Q | 30.06.2022 | 46 Tage | SEC » |
| 16.05.2022 | 10-Q | 31.03.2022 | 46 Tage | SEC » |
| 28.03.2022 | 10-K | 31.12.2021 | 87 Tage | SEC » |
| 15.11.2021 | 10-Q | 30.09.2021 | 46 Tage | SEC » |
| 16.08.2021 | 10-Q | 30.06.2021 | 47 Tage | SEC » |
Kapitalerhöhungen & Emissions-Historie
Emissions-Historie aus den finalen SEC-Prospekten: Börsengang (424B4) und Kapitalerhöhungen (424B5, Folge-/Sekundärplatzierungen). Volumen = Brutto-Erlös (bei Börsengängen zusätzlich der Ausgabepreis). Wiederholte Kapitalerhöhungen deuten auf Verwässerung der Altaktionäre hin.
| Datum (US) | Art | Volumen | |
|---|---|---|---|
| 13.11.2025 | Kapitalerhöhung | $50,0 Mio | SEC » |
| 20.07.2023 | Kapitalerhöhung | $130,0 Mio · $7,75/Aktie | SEC » |
| 17.07.2023 | Kapitalerhöhung | $100,0 Mio | SEC » |
| 27.04.2023 | Kapitalerhöhung | $50,0 Mio | SEC » |
| 02.07.2021 | Börsengang | $148,8 Mio · $16,00/Aktie | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). Beträge in US-Dollar.
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 23.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 23.04.2026 | HV-Einladung | 03.06.2026 Jahres-HV | 08.04.2026 | DEF 14A | SEC » |
| 23.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 23.04.2025 | HV-Einladung | 04.06.2025 Jahres-HV | 08.04.2025 | DEF 14A | SEC » |
| 22.04.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 22.04.2024 | HV-Einladung | 04.06.2024 Jahres-HV | 08.04.2024 | DEF 14A | SEC » |
| 28.04.2023 | HV-Einladung | — | — | DEFA14A | SEC » |
| 27.04.2023 | HV-Einladung | 06.06.2023 Jahres-HV | 10.04.2023 | DEF 14A | SEC » |
| 14.04.2023 | Vorläufig | — | — | PRE 14A | SEC » |
| 27.04.2022 | HV-Einladung | — | — | DEFA14A | SEC » |
| 27.04.2022 | HV-Einladung | 15.06.2022 Jahres-HV | 18.04.2022 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-29 | 49 | 2,36 | 116 |
| 2026-06-08 | 1.616 | 2,15 | 3.474 |
| 2026-05-11 | 5 | 2,56 | 13 |
| 2026-04-23 | 9.801 | 2,81 | 27.541 |
| 2026-03-27 | 63 | 2,55 | 161 |
| 2026-03-24 | 1.231 | 2,71 | 3.336 |
| 2026-03-20 | 142 | 2,92 | 415 |
| 2026-03-17 | 100 | 3,34 | 334 |
| 2026-03-16 | 2.808 | 3,27 | 9.182 |
| 2026-02-19 | 6 | 2,61 | 16 |
| 2026-02-09 | 586 | 2,40 | 1.406 |
| 2026-02-06 | 199 | 2,25 | 448 |
| 2026-02-04 | 123 | 2,57 | 316 |
| 2026-02-03 | 10.660 | 2,59 | 27.609 |